Table 2.

Infertility treatment characteristics

Characteristic	Myoma group	Non-myoma group	p value
AFC (n)	14 (6–23)	15 (9–25)	0.09
Baseline FSH (IU/L)	7 (6–8)	7 (6–8)	0.76
Primary IVF treatment factor (n (%)):
- Mechanical   - Ovulatory   - Endometriosis   - Male   - Unexplained	10 (10.0) 36 (35.6) 7 (6.9) 30 (29.7) 18 (17.8)	100 (9.8) 287 (28.2) 50 (4.9) 332 (32.6) 249 (24.5)	0.11
Embryo transfers (n (%)):
- Fresh   - Frozen	57 (56.4) 44 (43.6)	622 (61.1) 396 (38.9)	0.36
IVF protocol (n (%)):
- Antagonist   - Long agonist   - Microdose flare   - Natural frozen ET   - Artificial frozen ET	33 (32.7) 2 (2.0) 26 (25.7) 3 (3.0) 37 (36.6)	354 (34.8) 96 (9.4) 195 (19.2) 40 (3.9) 333 (32.7)	0.11
Stimulation in fresh ET cycles (n (%)):
- Recombinant FSH   - HMG	40 (70.2) 17 (30.9)	475 (76.4) 147 (23.6)	0.11
Total FSH dose in fresh IVF cycles (IU)	2325 (1350–4050)	2025 (1531–2700)	0.26
Peak estradiol (pmol/L)	4552 (3186–7225)	5748 (3534–8807)	0.09
Peak endometrial thickness (mm)	10.2 ± 2.4	10.2 ± 2.2	0.88
Number of retrieved oocytes (n)	11.1 ± 8.8	11.7 ± 7.9	0.49
Sperm volume (mL)	2 (1.1–3.0)	2.2 (1.5–3.0)	0.14
Sperm concentration (mln/mL)	28 (9–40)	20 (6–40)	0.97
Sperm motility (mean %)	30 (20–40)	25 (15–35)	0.08
ICSI cycles (n (%))	83 (82.2)	766 (75.2)	0.44
Cycles with top-quality transferred embryos (n (%))	79 (78.2)	816 (80.2)	0.64
Number of embryos per transfer (n)	1 (1–2)	1 (1–1)	0.12
Embryo stage at transfer (n (%)):
- Cleavage-stage   - Blastocyst	18 (17.8) 83 (82.2)	258 (25.3) 771 (74.7)	0.11
First beta-HCG value (mIU/mL)	369 (247–540)	382 (246–599)	0.65

Data are median (quartiles) or mean ± standard deviation unless stated otherwise

AFC, antral follicle count; FSH, follicle-stimulating hormone; IVF, in vitro fertilization; ET, embryo transfer; HMG, human menopausal gonadotropin; ICSI, intracytoplasmic sperm injection; HCG, human chorionic gonadotropin